TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06795412: Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

Sponsor: Pyxis Oncology, Inc · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 220 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$471,240

Rescue Site Savings

+$314,160

Unlock Full NCT06795412 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06795412 Rescue Dossier →